Furthermore, the GIADA trial (32) reported that the co-occurrence of a basal-like intrinsic subtype and high TILs in premenopausal patients with ER ≥10%/HER2-negative BC and a luminal B-like IHC profile could accurately predict pCR after ICI-based neoadjuvant treatment and ET. The gene discussed is ERBB2; the disease is breast cancer.